
Targeted TYK2 Blockade for PsO Without JAK1/2/3 Impact
Zasocitinib (TAK-279) has emerged as a leading investigational oral therapy in the treatment landscape for immune-mediated inflammatory diseases (IMIDs), including psoriasis and psoriatic arthritis. Developed as a highly selective allosteric inhibitor of …